Ratings Micro Digital Co., Ltd.

Equities

A305090

KR7305090003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8,570 ^KRW	-0.92%		-3.71%	+20.37%

Mar. 20	Micro Digital Co., Ltd. announced that it has received KRW 9 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Shinhan Bank Co., Ltd., NH Investment & Securities Co., Ltd., Winvest Venture Partners Inc.	CI
Mar. 18	Micro Digital Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Shinhan Bank Co., Ltd., NH Investment & Securities Co., Ltd., Winvest Venture Partners Inc. and another investor	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
MICRO DIGITAL CO., LTD.	+20.37%	98.31M	-
ABBOTT LABORATORIES	-6.46%	179B	C+
MEDTRONIC PLC	+3.39%	113B	C
BECTON, DICKINSON AND COMPANY	-3.68%	67.88B	A
DEXCOM, INC.	+5.44%	52.03B	B-
CENCORA, INC.	+5.70%	43.3B	B-
HOYA CORPORATION	+4.03%	41.79B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.42%	32.49B	B
TERUMO CORPORATION	+14.00%	25.65B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-4.29%	24.55B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes